MedPath

Pain Biomarker Study

Phase 1
Conditions
Migraine
Trigeminal Autonomic Cephalgia
Hemicrania Continua
Paroxysmal Hemicrania
Short-Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing
Cluster Headache
SUNCT
Interventions
Registration Number
NCT03511846
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

This study investigates molecular and physical biomarkers of headaches in order to better understand mechanisms of these diseases.

There are 3 main parts:

1. Use of capsaicin (active ingredient in hot chili peppers) to trigger release of calcitonin gene related peptide - the hypothesis is that this will be different in headache subjects compared to controls (and if so might be used to predict how these patients will respond to certain medications that modulate calcitonin gene-related peptide). Subjects will be given capsaicin as a cream applied to the forehead or the inner nostril, or a hot sauce that is ingested.

2. Use of capsaicin to trigger eye watering - the hypothesis is that oxygen gas will slow down the amount of eye watering. Cluster headache patients respond very powerfully to oxygen gas but to very little else. The mechanism for oxygen is unknown but in rodents there is data that it works on the parasympathetic / lacrimal gland system. This study translates rodent data into humans in a non-invasive way to confirm the mechanism of this very effective treatment.

3. Use of ice water to trigger headaches - brain freeze causes a very short-lived but intense headache that may cause similar biomarker release as other headache disorders. This may be a useful human model for other headache disorders.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
371
Inclusion Criteria
  • Diagnosis of one of the following: a. Diagnosis of a primary headache disorder according to the International Headache Classification, including migraine with aura, migraine without aura, chronic migraine, tension headache, cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and hemicrania continua; b. Diagnosed by a pain medicine physician with lumbar radiculopathy (possibly including neuropathic features, nerve impingement on MRI, or electromyography (EMG) report suggestive of lumbar radiculopathy); or c. Healthy control subject with no history of debilitating headaches or debilitating back pain / radiculopathy pain, and no headaches or back pain within the previous 3 months.
  • Able to provide HIPAA authorization to share prior medical records/imaging
  • Age 18 and older
Exclusion Criteria
  • The following items exclude the subject from all portions of the study: a. Known history of cardiovascular or neurovascular diseases. These diseases may include carotid stenosis of >50%, vertebral stenosis, peripheral vascular disease, angina or myocardial infarction, stroke, or vascular malformations; b. History of brain tumors or epilepsy; c. Active pregnancy or lactation; d. Daily cigarette, tobacco or nicotine use; e. Life expectancy less than 1 year, co-existing disease or other characteristic that precludes appropriate diagnosis of headache or spine pain; f. Active drug / alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements; or g. Inability or unwillingness of subject to give informed consent (e.g., ward of the state)
  • The following items exclude the subject only from the capsaicin portion of the study: a. Known allergy to capsaicin or hot peppers
  • The following items exclude the subject only from the oxygen portion of the study: a. Pulmonary or other non-headache diseases that require the use of supplemental oxygen
  • The following items exclude the subject only from the cold water irrigation (ice water) portion of the study: a. Trauma, fractures, or congenital abnormalities of the soft palate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Oral capsaicinOral capsaicin-
Oral capsaicin and Medical AirOral capsaicin-
Oral capsaicin and Medical AirMedical Air-
Oral Capsaicin and Low Flow OxygenLow Flow Oxygen-
Oral capsaicin and High Flow OxygenOral capsaicin-
Oral capsaicin and High Flow OxygenHigh Flow Oxygen-
Topical capsaicinTopical capsaicin-
Topical capsaicin and Medical AirTopical capsaicin-
Topical capsaicin and Medical AirMedical Air-
Topical capsaicin and Low Flow OxygenLow Flow Oxygen-
Topical capsaicin and High Flow OxygenTopical capsaicin-
Topical capsaicin and High Flow OxygenHigh Flow Oxygen-
Intranasal capsaicinIntranasal capsaicin-
Intranasal capsaicin and Medical AirIntranasal capsaicin-
Intranasal capsaicin and Medical AirMedical Air-
Intranasal capsaicin and Low Flow OxygenIntranasal capsaicin-
Intranasal capsaicin and Low Flow OxygenLow Flow Oxygen-
Intranasal capsaicin and High Flow OxygenIntranasal capsaicin-
Cold water irrigationCold Water Irrigation-
Cold water irrigation and Medical AirCold Water Irrigation-
Cold water irrigation and Medical AirMedical Air-
Cold water irrigation and Low Flow OxygenCold Water Irrigation-
Cold water irrigation and Low Flow OxygenLow Flow Oxygen-
Cold water irrigation and High Flow OxygenCold Water Irrigation-
Cold water irrigation and High Flow OxygenHigh Flow Oxygen-
Intranasal capsaicin and High Flow OxygenHigh Flow Oxygen-
Topical capsaicin and Low Flow OxygenTopical capsaicin-
Oral Capsaicin and Low Flow OxygenOral capsaicin-
Primary Outcome Measures
NameTimeMethod
Activation of trigeminoautonomic reflex as assessed by change in Calcitonin gene-related peptide (CGRP) levels from before stimulation to after stimulation.10 minutes before pain stimulation and 10 minutes, 20 minutes, 30 minutes, 60 minutes, and 90 minutes after pain stimulation
Activation of trigeminoautonomic reflex as assessed by tear fluid production90 minutes after pain stimulation

The amount of tear fluid after each intervention will be measured via Schirmer strips

Secondary Outcome Measures
NameTimeMethod
Activation of trigeminoautonomic reflex as assessed by dermal blood flow90 minutes after pain stimulation
Activation of trigeminoautonomic reflex as assessed by change in pituitary adenylate cyclase activating polypeptide-38 (PACAP-38) levels levels from before stimulation to after stimulation.10 minutes before pain stimulation and 10 minutes, 20 minutes, 30 minutes, 60 minutes, and 90 minutes after pain stimulation
Activation of trigeminoautonomic reflex as assessed by saliva production90 minutes after pain stimulation
Activation of trigeminoautonomic reflex as assessed by nasal fluid production90 minutes after pain stimulation
Activation of trigeminoautonomic reflex as assessed by tactile threshold measurement with von Frey Filaments90 minutes after pain stimulation

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath